• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Poland Pharmaceuticals and Healthcare Report Q2 2008 - Product Image

Poland Pharmaceuticals and Healthcare Report Q2 2008

  • ID: 604172
  • May 2008
  • Region: Poland
  • 66 pages
  • Business Monitor International


  • Eli Lilly
  • GlaxoSmithKline
  • Krka
  • Lek (Novartis/Sandoz)
  • Polpharma
  • MORE

The Poland Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Polands pharmaceuticals and healthcare industry.

Growth in Poland’s drug market is beginning to slow down although it should still remain robust over the forecast period. By 2012, BMI expects total drug expenditure to reach US$6.36bn by 2012, representing a compound annual growth rate (CAGR) of 4.39%. Slowing growth, however, could damage investment as companies that earlier pledged to invest in Poland are failing to follow through with announced plans. This has led to concerns about the future of the local industry, although the recent purchase of local leader Polpharma by Hungarys Gedeon Richter suggests much confidence still remains. The Polpharma deal was the stand out event in the last quarter. Richter became the largest pharmaceutical firm in the Central & Eastern European (CEE) region with the joint purchase of Polpharma and Russias Akrihin for US$1.46bn. As a result of the deals, Richter will have a market capitalisation of HUF923bn (US$5.3bn) taking it ahead of Slovenias Krka and the Czech Republics Zentiva. Richter bought a 99.7% stake in Polpharma READ MORE >


  • Eli Lilly
  • GlaxoSmithKline
  • Krka
  • Lek (Novartis/Sandoz)
  • Polpharma
  • MORE

Executive Summary
Poland Pharmaceuticals Industry SWOT
Poland Political SWOT
Poland Economic SWOT
Poland Business Environment SWOT
Table: Pharmaceutical Business Environment Rankings
Limits To Potential Returns
Poland - Market Summary
Regulatory Regime
Intellectual Property Developments
Pricing And Reimbursement Issues
Healthcare In Poland
Industry Forecast Scenario
Overall Market Forecast
Table: Poland’s Drug Market Indicators
Key Growth Factors - Industry
Table: Poland’s Health Expenditure Indicators
Key Growth Factors - Macroeconomic
Table: Poland - Economic Activity
OTC Market Forecast
Table: OTC Market Indicators (US$mn unless otherwise stated)
Patented Market Forecast
Table: Poland’s Patented Market Indicators
Generics Market Forecast
Table: Poland’s Generics Market Indicators
Trade Figures
Table: Poland’s Pharmaceutical Trade Indicators (US$mn)
Other Healthcare Data Forecasts
Table: Socio-Demographic Indicators
Key Risks To our Forecast Scenario
Competitive Landscape
Biotechnology Sector
Manufacturing Sector
Table: Polfa Warszawas Leading Prescription Products
Wholesale Sector
Retail Sector
Table: Poland’s Pharmacies And Pharmacy Market Ratios

Company Monitor
- GlaxoSmithKline
- Eli Lilly
- Krka
- Lek (Novartis/Sandoz)
- Pliva (Barr Pharmaceuticals)
- Polpharma

BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components

- GlaxoSmithKline
- Eli Lilly
- Krka
- Lek (Novartis/Sandoz)
- Pliva (Barr Pharmaceuticals)
- Polpharma

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos